drugset / Trial / NCT00034814

Multicenter Trial for Adults With Partial Seizures

NCT00034814

Phase 2 Completed 190 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
Treatment

Summary

To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients.

Timeline

Start
2002-01
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Talampanel Small molecule 25 mg
Subject Talampanel Small molecule 35 mg
Subject Talampanel Small molecule 50 mg

Indications